Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer

• Main Authors: Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo, Shunrong Ji
• Format: Article
• Language: English
• Published: BMC 2020-09-01
• Series: Experimental Hematology & Oncology
• Subjects: Tumor suppressor genes; Pancreatic cancer; Metabolic reprogramming; p53; Treatment
• Online Access: http://link.springer.com/article/10.1186/s40164-020-00179-x

Abstract Background Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer that is involved in the pathogenesis of cancers, and is intricately linked to gene mutations. Main text However, though oncogenes such as KRAS and c-Myc play important roles in the process, and have been extensively studied, no substantial improvements in the prognosis of pancreatic cancer have seen. Therefore, some scientists have tried to explain the mechanisms of abnormal cancer metabolism from the perspective of tumor suppressor genes. In this paper, we reviewed researches about how metabolic reprogramming was regulated by tumor suppressor genes in pancreatic cancer and their clinical implications. Conclusion Abnormal metabolism and genetic mutations are mutually causal and complementary in tumor initiation and development. A clear understanding of how metabolic reprogramming is regulated by the mutated genes would provide important insights into the pathogenesis and ultimately treatment of pancreatic cancer.